Core Insights - Novo Nordisk and Eli Lilly are currently the leading companies in the GLP-1 drug market, with increasing competition as more drugmakers enter the obesity treatment space, presenting a significant growth opportunity in healthcare [1] Company Overview - Structure Therapeutics is a smaller company that is developing a GLP-1 weight loss pill, aleniglipron, which is entering phase 3 trials this year [2] - The company has reported a placebo-adjusted weight loss of up to 15.3% on the highest dosage after 36 weeks, aligning its results with other leading weight loss treatments [2][3] Clinical Trials and Safety - Structure's management highlights that their trials are shorter than those of other GLP-1 drugmakers, which typically last over 60 weeks, making their early results promising [3] - The treatment has shown no liver injuries or significant side effects, indicating a favorable safety profile [3] Market Position and Valuation - Structure's CEO believes the company is next in line for regulatory approval after Eli Lilly and Novo Nordisk, but strong phase 3 trial results are necessary before approval can be obtained [4] - The stock has tripled in value over the past 12 months, suggesting that investors may have already priced in the potential approval of the drug, with a current market capitalization of $6.5 billion [5] Investment Considerations - While there may be further upside for Structure's stock, its elevated valuation raises caution for investors, as any setbacks could lead to a significant sell-off [6]

Core Insights - Bristol Myers Squibb (BMY) stock experienced a moderate rise following the announcement of adjusted earnings of $1.26 per share, surpassing analyst expectations of $1.23 per share [1] - The company reported fourth-quarter sales of $12.5 billion, exceeding the anticipated $12.28 billion [1] - In comparison to the previous year, Bristol Myers earned $1.67 per share on $12.34 billion in sales during the same period [1] Financial Performance - Adjusted earnings per share: $1.26, compared to analyst expectations of $1.23 [1] - Fourth-quarter sales: $12.5 billion, exceeding the forecast of $12.28 billion [1] - Year-over-year comparison: Previous year earnings were $1.67 per share on $12.34 billion in sales [1]

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE) securities between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”). The Complaint alleges that Defendants provided misleading stat ...

Core Viewpoint - CVS Health will replace Amgen and Eli Lilly's bone disease treatments with lower-cost alternatives in its preferred drug lists starting April 1 [1] Group 1 - CVS Health is making changes to its preferred drug lists to include more cost-effective options [1] - The decision reflects a broader trend in the healthcare industry towards reducing drug costs for consumers [1]

Core Insights - Bristol-Myers Squibb Company (BMY) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.26, exceeding the Zacks Consensus Estimate of $1.15, but down from $1.67 in the same quarter last year [1] - Total revenues reached $12.5 billion, surpassing the Zacks Consensus Estimate of $12.25 billion, and reflecting a 1% increase from the previous year [1] - The stock price increased following the better-than-expected quarterly results [1] Financial Performance - BMY's shares have increased by 28.5% over the past six months, while the industry has grown by 43.8% [2] - U.S. revenues remained flat year over year at $8.56 billion, while international revenues rose by 5% to $3.94 billion [3] - The Growth Portfolio revenues increased by 16% to $7.39 billion, primarily driven by immuno-oncology drugs like Opdivo [6][7] - The Legacy Portfolio revenues decreased by 15% to $5.11 billion, impacted by generic competition on key drugs, despite an 8% increase in Eliquis sales to $3.45 billion [11] Key Drug Performance - Opdivo sales increased by 9% year over year to $2.69 billion, surpassing estimates [8] - Yervoy contributed $810 million, up 20% year over year, and Reblozyl sales surged 22% to $666 million [9] - Breyanzi sales rose by 49% to $392 million, while Camzyos sales skyrocketed by 59% to $353 million [10] Cost and Margin Analysis - Adjusted gross margin decreased to 71.9% from 74% in the previous year due to a change in product mix [14] - Adjusted research and development expenses declined by 8% to $2.56 billion, and adjusted marketing, selling, and administrative expenses decreased by 1% to $2.09 billion [15] Future Guidance - For 2026, BMY provided revenue guidance of $46-$47.5 billion, supported by the Growth Portfolio's strong performance [17] - The company expects adjusted earnings to be in the range of $6.05-$6.35 for the full year, with the Zacks Consensus Estimate for 2026 EPS at $6.08 [17] Pipeline Updates - In December 2025, the FDA approved Breyanzi for adult patients with relapsed or refractory marginal zone lymphoma [18] - A supplemental biologics license application for Opdivo in combination with other drugs for Hodgkin lymphoma is under priority review, with a decision expected by April 8, 2026 [19]

ATLANTA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding Ultragenyx’s expected results for its Phase III Orbit and Cosmic Studies, including setrusumab’s potential and the risks inherent in the study protocols put forth. If you purchased Ultragenyx shares ...

Novo Nordisk CEO Mike Doustdar was in a meeting with investors on Thursday discussing the company's tough recent outlook when one interrupted him with shock news: U.S. telehealth firm Hims and Hers He... ...

Group 1: Jobless Claims Data - Initial Jobless Claims reached 231K, exceeding expectations of 212K and the previous week's 209K, marking the highest level of 2026 so far [2] - Continuing Claims increased to 1.844 million from a revised 1.819 million the prior week, still favorable compared to the past six months where it ranged between 1.93 and 1.97 million [3] Group 2: Earnings Reports - Bristol Myers-Squibb (BMY) reported earnings of $1.26 per share, beating the Zacks consensus of $1.15, resulting in a 9.57% earnings beat, with shares up 1.7% [4] - ConocoPhillips (COP) missed earnings estimates by 6 cents, reporting $1.02 per share, leading to a 5.6% earnings miss and a 3.3% drop in shares [5] - Ralph Lauren (RL) posted earnings of $6.22 per share, surpassing expectations of $5.80 with a 7.2% positive surprise, although shares fell 6.5% due to declining annualized revenue growth [6] - Tapestry (TPR) reported earnings of $2.69 per share, exceeding the Zacks consensus of $2.20, with shares up 5.9% [7] - Other notable earnings beats included Hershey's (HSY) at +21.28% and ArcelorMittal (MT) at +53.57%, while MasterCraft Boat (MCFT) had the largest beat at +81.25%, despite a revenue miss leading to a 1.2% drop in shares [8]

AbbVie Financial Performance - AbbVie reported net revenue of $16.6 billion in Q4 2025, marking a 10% year-over-year increase, slightly exceeding analyst expectations, primarily driven by a strong performance from Humira [2][3] - Humira generated $1.2 billion in revenue during Q4, which was nearly 30% higher than Wall Street expectations, despite its overall decline due to generic competition [3] - For the full year 2025, AbbVie achieved net revenue of $61.2 billion, reflecting an 8.6% annual gain, with adjusted diluted earnings per share projected between $14.37 to $14.57 for 2026 [5] Product Performance Insights - Most of AbbVie's products met analyst estimates, except for Rinvoq, which fell short with quarterly revenue of nearly $2.4 billion, marking the second consecutive quarter of underperformance [3][4] - Skyrizi, another key product, had only a slight beat in performance, raising investor concerns about competition in the immunology market, particularly regarding Rinvoq and Skyrizi's prospects in the inflammatory bowel disease market [4] Market Challenges - The vaccine market is facing significant challenges due to a sudden shift in U.S. vaccine policy, increasing skepticism, and declining immunization rates, which threaten sales and future research in the sector [5]

Bioxytran (OTCPK:BIXT) Conference February 05, 2026 10:30 AM ET Company ParticipantsDavid Platt - CEOConference Call ParticipantsNone - AnalystDavid PlattThank you for having me. My name is David Platt, and I will present Bioxytran. I'm the CEO of the company. Let's start. It's a company about complex carbohydrates, chemistry. For some reason, my slide... Okay. It's a public company, and symbol BIXT. And we're dealing with three main problem, which is in virology, in stroke, early stroke, and cancer metasta ...